Coherus BioSciences, Inc. (CHRS)

2,0400 +0,1100 (+5,70%) Börsenschluss: 04:00PM EDT

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530
https://www.coherus.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 306

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Dennis M. Lanfear	Chairman, President & CEO	1,82M	179,98k	1955
Mr. Bryan J. McMichael	Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller	615,07k	N/A	1979
Mr. Paul Reider	Chief Commercial Officer	854,06k	N/A	1970
Mr. Richard L. Hameister	Chief Technical Officer	N/A	N/A	N/A
Ms. Jami Taylor	Vice President of Investor Relations	N/A	N/A	N/A
Cheston Turbyfill	Vice President of Communications	N/A	N/A	N/A
Mr. Scott Saywell	Executive Vice President of Corporate Development	N/A	N/A	N/A
Ms. Rebecca Sunshine	Chief Human Resources Officer	N/A	N/A	1963
Mr. Michael Chen	Senior Vice President of Commercial Analytics & Trade	N/A	N/A	N/A
Dr. Theresa M. Lavallee Ph.D.	Chief Development Officer & Chairman of Scientific Advisory Board	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Corporate Governance

Coherus BioSciences, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.